Medical/Pharmaceuticals
Ascletis Announces IND Filing of Its Second FASN Inhibitor ASC60 for Advanced Solid Tumors Accepted by China NMPA
HANGZHOU, China and SHAOXING, China, Jan. 26, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: 1672) today announces that following the consultation with China National Medical Products Administration (NMPA), the Investigational New Drug (IND) application of its second fatty acid synthase (F...
2022-01-26 19:00
4386
Singapore Grants Approval for INDICAID COVID-19 Rapid Antigen Test as Consumer Self-test for SARS-CoV-2 Control
HONG KONG and SINGAPORE, Jan. 26, 2022 /PRNewswire/ -- PHASE Scientific
International LTD
2022-01-26 17:18
3931
Singapore Grants Approval for INDICAID COVID-19 Rapid Antigen Test as Consumer Self-test for SARS-CoV-2 Control
HONG KONG, Jan. 26, 2022 /PRNewswire/ -- PHASE Scientific International LTD
2022-01-26 17:15
3634
Venus Medtech Concludes Acquisition of 100% Equity Interest in Cardiovalve
HANGZHOU, China, Jan. 26, 2022 /PRNewswire/ -- Venus Medtech (Hangzhou) Inc. (Venus MedTech, 2500.HK), a leading, innovative Chinese structural heart disease treatment company, announced its acquisition of 100% equity interest in Cardiovalve Ltd. (Cardiovalve), a pioneering transcatheter mitral a...
2022-01-26 14:28
6298
RemeGen's Telitacicept Demonstrates Positive Results in Phase II Trial in Treatment of Primary Sjögren's Syndrome
YANTAI, China, Jan. 26, 2022 /PRNewswire/ -- RemeGen Co., Ltd. (9995.HK), a commercial-ready biotechnology company, recently announced positive results from the completion of its Phase II trial inChina for Telitacicept in the treatment of primary Sjögren's syndrome ("pSS"). A total of 42 patient...
2022-01-26 10:52
4741
GenScript ProBio Initiates a CDMO Contract For Next-Generation CD47 Antibody with InnoBation Bio
SEOUL, South Korea, Jan. 26, 2022 /PRNewswire/ -- GenScript ProBio, a global biopharmaceutical contract development and manufacturing organization (CDMO), announced onJanuary 26th, 2022 that it entered into a contract with InnoBation Bio to develop and manufacture clinical trial sample substances...
2022-01-26 09:00
3672
SNIPR BIOME Announces U.S Food and Drug Administration grants Fast Track Designation for SNIPR001 for Prevention of Bloodstream Infections in Hematologic Cancer Patients
COPENHAGEN, Denmark, Jan. 25, 2022 /PRNewswire/ -- SNIPR BIOME ApS, a leading CRISPR and microbiome biotechnology company, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for SNIPR001. SNIPR001 is the company's first development candidate targeting E. coli i...
2022-01-25 22:42
2476
2022 Japan Prize Laureates Announced
TOKYO, Jan. 25, 2022 /PRNewswire/ -- The Japan Prize Foundation announced the winners of the 2022 Japan prize onJanuary 25. Prof. Katalin Kariko (Hungary/USA ) and Prof.Drew Weissman (USA) are co-winners of the Japan Prize in the field of "Materials and Production," and Prof.Christopher Field (USA...
2022-01-25 14:00
1126
Insilico Medicine Applauded by Frost & Sullivan for Enabling Rapid and Cost-Effective Drug Discovery and Development with Its Pharma.AI Platform
The Pharma.AI platform combining deep generative models (GAN), reinforcement learning (RL), transformers, and other modern machine learning techniques enables the identification of novel targets,generation of novel molecules non-existent in the chemical space, and prediction of outcomes for clini...
2022-01-25 13:23
2491
IMPRESSION Randomized Trial: Past the halfway mark and progressing rapidly
SINGAPORE, Jan. 24, 2022 /PRNewswire/ -- Concept Medical Inc.,
2022-01-24 23:35
4336
MGI's New MGISP-Smart 8 Automated Sample Preparation System Makes International Debut at MEDLAB Middle East
DUBAI, UAE, Jan. 24, 2022 /PRNewswire/ -- MGI Tech Co., Ltd. ("MGI"), a global life science leader and innovator, has unveiled its new MGISP-Smart 8 automated sample preparation system to the world at MEDLAB Middle East, which kicked off today at the Dubai World Trade Center. The event marks the ...
2022-01-24 19:30
2266
Innovent Announces the Approval of Pemazyre® (pemigatinib) in Hong Kong Market for the Treatment of Adults With Locally Advanced Or Metastatic Cholangiocarcinoma With A FGFR2 Fusion Or Rearrangement That Have Progressed After At Least One Prior Line Of Systemic Therapy
SAN FRANCISCO and SUZHOU, China, Jan. 24, 2022 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseas...
2022-01-24 15:22
5468
Applied Pharmaceutical Science Inc. Announces FDA Approval of Investigational New Drug Application for APS03118, a Next generation RET Original New Drug for Unlimited Cancers
BEIJING and PHILADELPHIA, Jan. 24, 2022 /PRNewswire/ -- Applied Pharmaceutical Science, Inc. ("APS" or "the Company"), has recently announced the Investigational New Drug (IND) application for its self-developed breakthrough new drug APS03118, a next generation selective RET inhibitor, has been a...
2022-01-24 13:10
3921
New York Medical Group Publishes Research on Tech Neck
NEW YORK, Jan. 24, 2022 /PRNewswire/ -- New York Medical Group
2022-01-24 12:39
2568
Ascletis Announces First Patient Dosed in the Phase III Clinical Trial of FASN Inhibitor ASC40 Combined with Bevacizumab for Treatment of Recurrent Glioblastoma
HANGZHOU and SHAOXING, China, Jan. 23, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: 1672) today announces the dosing of the first patient in the Phase III registration clinical trial of ASC40 combined with bevacizumab for treatment of recurrent glioblastoma (rGBM). ASC40 is an oral, sele...
2022-01-23 18:35
5344
Innovent and Eli Lilly and Company Announced Final Clinical Results and Biomarker Analysis of Phase Ib Study of TYVYT® (Sintilimab Injection) Plus Bevacizumab Biosimilar Injection for Advanced Hepatocellular Carcinoma at ASCO GI Annual Meeting 2022
SAN FRANCISCO and SUZHOU, China, Jan. 22, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major disea...
2022-01-22 08:00
9499
Swiss Pharma Company - IDEOGEN takes over Special Access Program for BELEODAQ® (belinostat)
HURDEN, Switzerland, Jan. 22, 2022 /PRNewswire/ -- IDEOGEN GROUP, Managed Access division, takes over Special Access Program for BELEODAQ® (belinostat) in Europe, Middle East, North Africa, Russia, and CIS. BELEODAQ® is a prescription medicine used to treat patients with a rare form of blood canc...
2022-01-22 04:24
5331
Sihuan Pharmaceutical (0460.HK): Establishment of Joint Venture with Bluepha Co., Ltd.
HONG KONG, Jan. 21, 2022 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Co., Ltd. (the "Company" or "Sihuan Pharmaceutical", together with its subsidiaries, collectively referred to as the "Group:" Hong Kong Stock Exchange Stock Code: 0460) is pleased to announce thatBeijing MeiYan KongJian...
2022-01-21 11:12
6729
Hinova Announces First Patient Dosed in a Phase I Clinical Trial of HP518, an orally bioavailable Chimeric Degrader targeting Androgen Receptor for Prostate Cancer Treatment
MELBOURNE, Australia, Jan. 21, 2022 /PRNewswire/ -- Hinova Pharmaceuticals Inc., a clinical-stage biopharmaceutical company focused on developing novel therapeutics for cancers and metabolic diseases through targeted protein degradation technologies, announced that the first patient with metastat...
2022-01-21 05:30
3006
Suvoda Exceeds 2021 Targets; Poised for Continued Growth Supporting Complex Clinical Trials in 2022
Surpasses 900 trials across 65 countries, expands leadership team and product offerings, and posts another year of 30% growth, all while maintaining an exceptional performance level. PHILADELPHIA, Jan. 20, 2022 /PRNewswire/ -- Suvoda, LLC, a global clinical trial technology company that speciali...
2022-01-20 23:05
2945
Week's Top Stories
Most Reposted
Visa returns as title sponsor for 2026 MAMA AWARDS; Visa Presale registration begins 13 October
[Picked up by 310 media titles]
2026-10-13 10:00
Agoda and Emerging Travel Group Enter Strategic Partnership
[Picked up by 293 media titles]
2026-10-15 16:00Food & Hospitality Asia 2027 Redefining Excellence: The Premier Platform for Food & Beverage and Hospitality Innovation
[Picked up by 282 media titles]
2026-10-15 10:00Leading Asian DMC Discova to Attend ITB Asia 2026
[Picked up by 280 media titles]
2026-10-15 12:59
DayOne Upsizes Malaysia Financing to US$7.2 Billion; Total Billings Surpass 1GW and Bookings Reach 2.3GW
[Picked up by 270 media titles]
2026-10-14 18:01Most Read
Sonilo Raises $11M to Build the AI-Native Audio Stack for Video
2026-10-15 00:00
21393
Visa returns as title sponsor for 2026 MAMA AWARDS; Visa Presale registration begins 13 October
2026-10-13 10:00
20007
Agoda and Emerging Travel Group Enter Strategic Partnership
2026-10-15 16:00
9967